ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 415,95
-0,10%
Dow Jones
44 148,56
0,00%
DAX
20 400,04
-0,07%
Brent Oil
73,235
-0,29%
Bitcoin
101 089,35
-0,10%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Inkine Pharmaceutical (MM) (INKP) Cours

Inkine Pharmaceutical (MM)

Inkine Pharmaceutical (MM) (INKP)

NASDAQ
0,00
0,00
(0,00%)
Fermé 12 Décembre 10:00PM
Retardé de 15 minutes
0,00
0,00
( 0,00% )
Avant marché: -
Retardé de 15 minutes

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Statistiques et détails clés

Dernier
-
Prix Achat
-
Prix Vente
-
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
-
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

INKP Dernières nouvelles

Plus de nouvelles

Inkine Pharmaceutical Announces Approval of Merger with Salix Pharmaceuticals

InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) and Salix Pharmaceuticals, Ltd. (Nasdaq: SLXP) announced that earlier today the shareholders of both companies approved the merger of the two...

30 Septembre 2005
Business Wire

Nation's Leading Independent Proxy Advisory Firm Recommends That InKine Shareholders Vote in Favor of Merger with Salix Pharmace

InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that Institutional Shareholder Services (ISS), the nation's leading independent proxy advisory firm, has recommended that...

20 Septembre 2005
Business Wire

InKine Reports Second Quarter 2005 Financial Results

InKine Pharmaceutical Company, Inc. (Nasdaq: INKP): ? Highlights ? -- Entered into a definitive merger agreement with Salix Pharmaceuticals, Ltd. ? -- Filed New Drug Application (NDA) for...

08 Août 2005
Business Wire

InKine Reports Seven INKP-102 Study Data Abstracts Accepted for Presentation at the Annual Scientific Meeting of the American Co

InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that seven abstracts with data from clinical studies of the Company's next-generation purgative product, INKP-102, have...

03 Août 2005
Business Wire

Salix Pharmaceuticals to Acquire InKine Pharmaceutical; Strategic Combination Creates Leading Specialty Pharmaceutical Company F

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) and InKine Pharmaceutical Company, Inc. (NASDAQ: INKP) announced today that the two companies have entered into a definitive merger agreement under which...

23 Juin 2005
Business Wire

InKine Announces Final Court Approval in Securities Class Action Litigation

InKine Pharmaceutical Company, Inc. (Nasdaq:INKP) today announced that the Philadelphia Court of Common Pleas entered a final judgment order approving the settlement of InKine's class...

16 Juin 2005
Business Wire

InKine Reports First Quarter 2005 Financial Results: Realizing Profitability While Accelerating the Development of INKP-102

InKine Pharmaceutical Company, Inc. (NASDAQ:INKP): -Highlights- ? -- Completed Phase III Clinical Study and Submitted a New Drug Application to FDA for Approval of INKP-102 ? -- Grew...

03 Mai 2005
Business Wire

InKine Announces Submission of a New Drug Application -NDA- for Its Next Generation Purgative Product - INKP-102

InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that on April 29, 2005 the Company submitted an electronic New Drug Application (NDA) for the United States marketing approval...

03 Mai 2005
Business Wire
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
PALIPalisade Bio Inc
US$ 3,20
(128,57%)
20,1M
SYTASiyata Mobile Inc
US$ 1,05
(40,37%)
12,24M
TRVITrevi Therapeutics Inc
US$ 3,40
(36,55%)
2,47M
ZENAZenaTech Inc
US$ 7,46
(31,11%)
3,6M
ATLNAtlantic International Corporation
US$ 7,00
(22,74%)
1
KROSKeros Therapeutics Inc
US$ 18,78
(-72,64%)
609,66k
SPGCSacks Parente Golf Inc
US$ 0,50
(-64,29%)
163,73k
PNBKPatriot National Bancorp Inc
US$ 1,08
(-58,78%)
16
AVGRAvinger Inc
US$ 0,441
(-46,22%)
87,3k
HEPAHepion Pharmaceuticals Inc
US$ 0,36
(-38,46%)
1
PALIPalisade Bio Inc
US$ 3,20
(128,57%)
20,1M
CDTConduit Pharmaceuticals Inc
US$ 0,1012
(14,61%)
14,2M
AMPGAmplitech Group Inc
US$ 2,20
(13,99%)
13,48M
SYTASiyata Mobile Inc
US$ 1,05
(40,37%)
12,24M
LAESSEALSQ Corporation
US$ 1,245
(8,26%)
8,74M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
INKP
Inkine Pharmaceutical
NASDAQ
ISRL
Israel Acquisitions
LSE
0QR8
Medicalgorithmics
COIN
EVAAUSD
Evanesco Network
COIN
EURTEUR
Euro Tether
COIN
ENJKRW
Enjin Coin
BIT
WAGA25
Agatos
BIT
UB4QEG
Unicredit Bank
BIT
UC7XES
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés